



# DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

## A Genome-Wide RNAi Screen in *Caenorhabditis elegans* Identifies the Nicotinic Acetylcholine Receptor Subunit ACR-7 as an Antipsychotic Drug Target

The Harvard community has made this article openly available. [Please share](#) how this access benefits you. Your story matters.

|                          |  |
|--------------------------|--|
| <b>Citation</b>          | Saur, Taixiang, Sarah E. DeMarco, Angelica Ortiz, Gregory R. Sliwoski, Limin Hao, Xin Wang, Bruce M. Cohen, and Edgar A. Buttner. 2013. A genome-wide RNAi screen in <i>Caenorhabditis elegans</i> identifies the nicotinic acetylcholine receptor subunit ACR-7 as an antipsychotic drug target. <i>PLoS Genetics</i> 9(2): e1003313.           |
| <b>Published Version</b> | <a href="https://doi.org/10.1371/journal.pgen.1003313">doi:10.1371/journal.pgen.1003313</a>  |
| <b>Accessed</b>          | February 19, 2015 12:01:51 PM EST  |
| <b>Citable Link</b>      | <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:10612559">http://nrs.harvard.edu/urn-3:HUL.InstRepos:10612559</a>  |
| <b>Terms of Use</b>      | This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a> |

*(Article begins on next page)*

# A Genome-Wide RNAi Screen in *Caenorhabditis elegans* Identifies the Nicotinic Acetylcholine Receptor Subunit ACR-7 as an Antipsychotic Drug Target

Taixiang Saur<sup>1,2</sup>, Sarah E. DeMarco<sup>2</sup>, Angelica Ortiz<sup>3</sup>, Gregory R. Sliwoski<sup>4</sup>, Limin Hao<sup>1,2</sup>, Xin Wang<sup>1,2</sup>, Bruce M. Cohen<sup>1,2</sup>, Edgar A. Buttner<sup>1,2,5\*</sup>

**1** Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, United States of America, **2** Mailman Research Center, McLean Hospital, Belmont, Massachusetts, United States of America, **3** Department of Molecular Pathology, University of Texas—MD Anderson Cancer Center, Houston, Texas, United States of America, **4** Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America, **5** Department of Neurology, Harvard Medical School, Boston, Massachusetts, United States of America

## Abstract

We report a genome-wide RNA interference (RNAi) screen for Suppressors of Clozapine-induced Larval Arrest (*scla* genes) in *Caenorhabditis elegans*, the first genetic suppressor screen for antipsychotic drug (APD) targets in an animal. The screen identifies 40 suppressors, including the  $\alpha$ -like nicotinic acetylcholine receptor (nAChR) homolog *acr-7*. We validate the requirement for *acr-7* by showing that *acr-7* knockout suppresses clozapine-induced larval arrest and that expression of a full-length translational GFP fusion construct rescues this phenotype. nAChR agonists phenocopy the developmental effects of clozapine, while nAChR antagonists partially block these effects. ACR-7 is strongly expressed in the pharynx, and clozapine inhibits pharyngeal pumping. *acr-7* knockout and nAChR antagonists suppress clozapine-induced inhibition of pharyngeal pumping. These findings suggest that clozapine activates ACR-7 channels in pharyngeal muscle, leading to tetanus of pharyngeal muscle with consequent larval arrest. No APDs are known to activate nAChRs, but a number of studies indicate that  $\alpha 7$ -nAChR agonists may prove effective for the treatment of psychosis.  $\alpha$ -like nAChR signaling is a mechanism through which clozapine may produce its therapeutic and/or toxic effects in humans, a hypothesis that could be tested following identification of the mammalian ortholog of *C. elegans* *acr-7*.

**Citation:** Saur T, DeMarco SE, Ortiz A, Sliwoski GR, Hao L, et al. (2013) A Genome-Wide RNAi Screen in *Caenorhabditis elegans* Identifies the Nicotinic Acetylcholine Receptor Subunit ACR-7 as an Antipsychotic Drug Target. PLoS Genet 9(2): e1003313. doi:10.1371/journal.pgen.1003313

**Editor:** Ethan Oren Perlestein, Lewis-Sigler Institute for Integrative Genomics, United States of America

**Received:** August 7, 2012; **Accepted:** December 22, 2012; **Published:** February 28, 2013

**Copyright:** © 2013 Saur et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** The work was supported by an NIH Clinical Scientist Development award K08NS002083, a Shervert Frazier Research Institute Grant, and a NARSAD Young Investigator Award to EAB and by a Stanley Medical Research Institute Grant to BMC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: ebuttner@partners.org

## Introduction

Treatment of psychotic disorders has been hampered by the limited efficacy of currently available APDs and the toxic side effects of these drugs [1]. Clozapine is the most effective medication for treatment-refractory schizophrenia but produces toxic side effects such as agranulocytosis, metabolic syndrome, and developmental defects after exposure early in life [2–4]. The molecular mechanisms underlying the therapeutic and toxic side effects of clozapine and other APDs remain poorly understood [5,6]. A better understanding of these mechanisms could facilitate the design of superior drugs and may inform our understanding, not only of drug mechanisms, but also of disease pathogenesis. For example, studies of antidepressant drug mechanisms have produced new insight into the important role of neurogenesis in depression itself [7,8].

The genetic tools of invertebrate models offer new paradigms for drug discovery in schizophrenia [9,10]. Pharmacogenetic experiments in *Caenorhabditis elegans* identify novel and important signal transduction pathways through which APDs exert their biological effects [11–14]. Large-scale genetic screens in *C. elegans*

provide an unbiased approach to discover genetic targets of APDs, and such experiments are not possible in knockout or transgenic mice. Using such an unbiased approach, we identified a potential APD target with homology to human brain receptors.

We found that loss-of-function mutations in *acr-7*, which encodes a homolog of the human  $\alpha$ -like nAChRs, suppressed both developmental and behavioral effects of clozapine. Our results indicated that clozapine likely activated the ACR-7 receptor, a novel observation that may be relevant to clinical drug effects. No known APDs have been previously demonstrated to activate nAChRs, and whether APDs might act by this mechanism is an important question. Recent studies in humans have underscored the potential importance of nAChRs in the pathophysiology of schizophrenia owing to: (1) the abnormal expression of nAChRs in post-mortem brains of schizophrenic patients; (2) the striking association between smoking (a nicotine delivery system) and schizophrenia; (3) the improved cognition seen in animals and humans with nicotine exposure; (4) the genetic association between the human  $\alpha 7$ -nAChR and schizophrenia; and (5) the potential efficacy of nAChR agonists as treatments for schizophrenia [15–17].

## Author Summary

Clozapine is the most effective medication for treatment-refractory schizophrenia but produces toxic side effects such as agranulocytosis, metabolic syndrome, and developmental defects after exposure early in life. However, clozapine's molecular mechanisms of action remain poorly understood. In past studies, we showed that pharmacogenomic experiments in *C. elegans* identify novel signaling pathways through which clozapine exerts its biological effects. Here, we report the first genetic suppressor screen for antipsychotic (APD) drug targets in an animal and identify 40 suppressors of clozapine-induced larval arrest, including the  $\alpha$ -like nicotinic acetylcholine receptor (nAChR) *acr-7*. We validate our RNAi result by showing that an *acr-7* knockout suppresses clozapine-induced larval arrest and inhibition of pharyngeal pumping. Expression of a full-length translational *acr-7::GFP* (Green Fluorescent Protein) construct in the *acr-7* mutant rescues suppression of these phenotypes. Clozapine-induced phenotypes are phenocopied by nAChR agonists and blocked by nAChR antagonists. The results suggest that clozapine induces these phenotypes through activation of the ACR-7 receptor. Recent studies have underscored the potential importance of nAChRs in the pathophysiology of schizophrenia. A clearer understanding of APD mechanisms would facilitate the design of improved drugs and may inform our understanding, not only of drug mechanisms, but also of disease pathogenesis.

## Results

### A chemical genetic screen for APD targets

To identify novel molecular mechanisms of action of APDs, we conducted a genetic suppressor screen for APD targets in an animal [18]. APDs cause larval arrest or developmental delay in *C. elegans* (Figure 1B). APDs inhibit pharyngeal pumping [12,19,20], indicating that the developmental phenotype has a neuromuscular basis. To identify potential APD targets, we performed a genome-wide RNAi screen for Suppressors of Clozapine-induced Larval Arrest (*scla* genes). Mutants that escaped clozapine-induced larval arrest grew to adulthood and were easily detected under a dissecting microscope (Figure 1B, [21]). The experimental design is outlined in Figure 1A and involved a primary RNAi screen in liquid culture followed by triplicate testing in agar wells. To ensure adequate knockdown of potential targets, we exposed animals to two rounds of RNAi and tested progeny in the second generation. We also employed the NL4256 *rnf-3(pk1426)* II strain, which is hypersensitive to RNAi and which improves detection of genes with postembryonic mutant phenotypes, to maximize recovery of neuronal genes [22].

Of the 19,968 wells we tested in the primary screen, 1,375 wells or 6.9% displayed suppression of clozapine-induced larval arrest. *magi-1*, a membrane-associated guanylate kinase gene, and *sec-8*, an exocyst complex gene, were each identified as positives twice in the primary screen. Subsequent testing of primary screen positives in triplicate identified 40 candidate suppressors, constituting 0.2% of the total wells screened (Table 1). To rule out false positives, we collected viable knockout mutants corresponding to our RNAi suppressors and tested them for suppression of clozapine-induced larval arrest. These knockouts included strains *acr-7(tm863)*, *cep-1(ep347)*, *cep-1(gk138)*, *cep-1(lg12501)*, *gtl-2(n2618)*, *gtl-2(tm1463)*, *ina-1(gm39)*, *ins-22(ok3616)*, *lon-6(ok1119)*, *magi-1(gk657)*, *puf-6(ok3044)*, *scla-1(tm4534)*, *scla-1(tm4806)*, and *sms-1(ok2399)*.


Suppression of clozapine-induced larval arrest was seen in 70% of the RNAi screen positives when tested by knockout rather than by RNAi knockdown, including *acr-7*, *gtl-2*, *ina-1*, *magi-1*, *puf-6*, *sms-1*, and *scla-1*. The *cep-1*, *ins-22*, and *lon-6* knockout strains failed to suppress clozapine-induced larval arrest, suggesting that these suppressors were false positives. Alternatively, suppression may occur in these three cases with partial loss-of-function by RNAi knockdown, but not with complete loss-of-function by knockout.

Chemicals such as paraquat are commonly used to study the genetics of stressor-induced developmental delay or lethality in *C. elegans*. We asked whether genes recovered in our RNAi screen suppress the effects of stressors, including paraquat, DTT, SDS, and tunicamycin [23–26]. Tunicamycin up to 10  $\mu$ g/ml and DTT at 5 mM produced no or mild developmental delay in N2 animals (data not shown). More robust effects were seen with 0.01% SDS or 0.2–0.5 mM paraquat (Figure S1). Developmental delay in N2 animals was compared with that in *sms-1(ok2399)*, *age-1(hx546)*, *scla-1(tm4806)*, *scla-1(tm4534)*, and *acr-7(tm863)* mutant strains. None of these mutant strains grew more rapidly in the presence of SDS or paraquat than N2 animals, suggesting that these mutations did not act by suppressing stressor effects (Figure S1). Rather, the suppression seen with these mutations appeared to be specific for the developmental effects of clozapine. Stressor-induced lethality was also scored, and, similar to the results of the developmental delay assay, no suppression was seen with these mutations (data not shown).

The functional classes of the suppressors revealed that a more diverse group of genes was required for the biological effects of clozapine than had been previously appreciated. A fraction of these genes likely suppressed clozapine-induced larval arrest via indirect effects. However, molecules involved in signal transduction significantly outnumbered those in other functional classes, consistent with the idea that clozapine's developmental effects have a neuromuscular basis (Figure 2, [12,19]). Moreover, the fraction of signal transduction genes from our RNAi screen was higher than that from a screen for all genes with RNAi phenotypes in *C. elegans* [27]. This difference indicated that our dataset was specific to the effects of clozapine.

### *acr-7* sequence and homology

We sought to understand the molecular mechanisms of action of the RNAi suppressors in detail and chose to focus initially on *acr-7*. The rationale for focusing on *acr-7*, as opposed to other new candidate APD targets, included potential relevance to psychotic disorders [15–17], probability of a human ortholog [28,29], and potential for physiological characterization [30]. Blasting the ACR-7 protein sequence against the human genome using Wormbase BLAT revealed that ACR-7 is homologous to a number of human  $\alpha$ -like nAChRs, but which human gene is the true *acr-7* ortholog is not known. Homology comparisons with the human  $\alpha 7$ -nAChR showed 36% identity overall and greater identity within the first two predicted transmembrane domains of the ion channel (Figure 3A). The pore-lining transmembrane domain II (M2) and neighboring residues play an important role in the ion selectivity filter of nAChRs. Specifically, substitution of the glutamate residue immediately preceding M2 or the glutamate residue at the extracellular mouth of the pore significantly reduces the calcium permeability of various nAChR subunits [31]. We noted that both glutamate residues are conserved in ACR-7, suggesting that, like the human  $\alpha 7$ -nAChR, ACR-7 is highly permeable to calcium. Our attempts to obtain voltage-clamp recordings of ACR-7 expressed in heterologous systems, including *Xenopus laevis* oocytes and cultured HEK293T and PC12 cells,



**Figure 1. A genome-wide RNAi screen for *scla* genes yielded the nAChR gene *acr-7*.** (A) Experimental design of the feeding RNAi screen in liquid culture. On day 1, *rrf-3* animals were synchronized, and bacteria was cultured from the Ahringer RNAi feeding library. Synchronized L1 animals were added to induced cultures on day 2 and were allowed to grow to adulthood for 3 days. Clozapine was added on day 5, and progeny were allowed to develop for 3 days. Progeny were scored for the *Scla* phenotype on day 8. (B1) N2 animals grew to adulthood within 3 days in the presence of 0.1% DMSO alone. (B2) 320  $\mu$ M clozapine caused larval arrest in N2 animals exposed to feeding RNAi bacteria with empty vector alone. (B3) *acr-7(RNAi)* animals in 0.1% DMSO alone displayed normal development. (B4) *acr-7(RNAi)* suppressed developmental delay caused by 320  $\mu$ M clozapine. (B5) The *acr-7(tm863)* knockout suppressed developmental delay caused by 320  $\mu$ M clozapine. Note that experiments depicted in (B) were performed on NGM plates, not in liquid culture, to allow clear photographs.  
doi:10.1371/journal.pgen.1003313.g001

failed, consistent with the possibility that ACR-7 is a subunit of a heteromeric channel [32,33].

### Knockout of *acr-7* suppressed clozapine-induced larval arrest

We tested growth effects over a range of clozapine concentrations (40–320  $\mu$ M). N2 animals grown in the presence of 0.1% DMSO alone reached adulthood in  $\sim$ 3 days (Figure 1B and Figure 4A). Consistent with our previous study [12], clozapine inhibited the development of N2 animals in a dose-dependent fashion. For example, 98% of control animals were gravid adults on day 3, compared to 36% on 80  $\mu$ M clozapine and 0% on 320  $\mu$ M clozapine (Figure 1B and Figure 4A).

The *acr-7(tm863)* allele is a 625 bp out-of-frame deletion with a 7 bp insertion, which removes exons 6–7 and most of exons 5 and 8 (Figure 3B) and lacks all four transmembrane domains (Figure 3C). Therefore, *acr-7(tm863)* is predicted to be a null allele. We backcrossed the *acr-7(tm863)* allele to the wild-type strain six times to generate the strain EAB200, which, like animals exposed to *acr-7(RNAi)* (Figure 1B), displayed normal development and normal adult morphology. On 320  $\mu$ M clozapine, 95% of *acr-7(tm863)* mutant animals reached the L4 and young adult (YA) stages by day 3, compared to 0% of N2 animals (Figure 1B and Figure 4A). Therefore, *acr-7(tm863)* partially suppressed clozapine-induced developmental delay, confirming the knockdown results from our RNAi screen. Transgenic strain *acr-7(tm863) II mchEx40*, which expresses a full-length translational *Pacr-7::acr-7::GFP* (Green Fluorescent Protein) fusion construct, was rescued for the *Scla* phenotype. On 320  $\mu$ M clozapine, 100% of these transgenic animals were arrested at early larval stages (L1, L2, and L3) on day

3, comparable to the delay seen in N2 animals (Figure 4A). We investigated the specificity of *acr-7(lf)* suppression by testing mutations in 21 other *C. elegans* nAChR subunits and found that only *acr-7(lf)* suppressed clozapine-induced developmental delay (Figure 5).


### Developmental effects of nAChR agonists and antagonists

To determine the mechanism of action of clozapine, we tested the nAChR agonists nicotine and levamisole [29] and found that they inhibited growth in a dose-dependent fashion, phenocopying the effects of clozapine. Only 3% of N2 animals grew to young adults or beyond by day 3 on 1 mM nicotine, compared to 100% of control animals (Figure 4B). On 10 mM levamisole, all N2 animals were arrested at the L1–L2 stages on day 3 (Figure 4B). Similar to its suppression of clozapine-induced developmental delay, the *acr-7(tm863)* mutation suppressed nicotine-induced developmental delay (Figure 4C). This suppression was partially rescued in *acr-7(tm863) II mchEx40* animals (Figure 4C). We also found that clozapine-induced larval arrest was blocked by the nAChR antagonists d-tubocurarine (d-TC) and dihydro-beta-erythroidine (DH $\beta$ E) [29]. In 320  $\mu$ M clozapine alone, 96% of N2 animals were arrested at the L1–L2 stages on day 3, compared to 25% in the presence of 500  $\mu$ M d-TC and 41% in the presence of 500  $\mu$ M DH $\beta$ E (Figure 4D). N2 animals displayed normal development in the presence of d-TC or DH $\beta$ E alone, consistent with the normal development seen with *acr-7* knockdown or knockout (Figure 4D). Taken as a whole, our results were consistent with the notion that *acr-7* encodes a nAChR and that clozapine activates ACR-7. Suppression of the developmental

**Table 1.** Summary of *scla* genes recovered in genome-wide RNAi screen.

| Sequence Name  | Locus               | Functional Group            | Brief Description                               | Score     | Hs            | Mm            | Dm                   | Sc      |
|----------------|---------------------|-----------------------------|---|-----------|---------------|---------------|----------------------|---------|
| C02F12.3       | <i>snct-1</i>       | Unknown                     | Novel protein                                   | +         |               |               |                      |         |
| C05E4.6        | <i>str-134</i>      | Signal transduction         | 7-transmembrane receptor                        | ++        | OR1-11        |               |                      |         |
| C14C6.8        |                     | Unknown                     | Extracellular protein with conserved cysteines  | +++       |               |               | CG12910              |         |
| C30H7.2        |                     | Metabolism                  | Thioredoxin                                     | +         | TXNDC4        | Txndc4        | CG9911               | PDI1    |
| C42C1.1        | <i>sre-14</i>       | Signal transduction         | G protein-coupled 7-transmembrane receptor      | +         |               |               |                      |         |
| F01G4.2        | <i>ard-1</i>        | Metabolism                  | Short chain dehydrogenase                       | ++        | HSD17B10      | Hsd17b10      | scu                  | YDL114W |
| F07A11.1       |                     | Cell structure              | Trichohyalin                                    | NA        | TCHH          | Gigyf2        |                      |         |
| F12F6.3        | <i>rib-1</i>        | Cell surface                | Exostosis-like protein                          | +         | EXT1          | Ext1          | ttv                  |         |
| F18A11.1       | <i>puf-6</i>        | Protein synthesis           | Pumilio family RNA binding protein              | +         | PUM1          | Pum1          |                      | PUF3    |
| F22B3.8        | <i>scla-1</i>       | Signal transduction         | Tyrosine kinase                                 | +++       | ITK           | Srms          | Fps85D               | CDC15   |
| F36H1.1        | <i>fkf-1</i>        | Protein turnover            | FK506-binding protein                           | ++        | FKBP2         | Fkbp2         | CG14715              | FPR2    |
| F37E3.2        | <i>Iron-6</i>       | Protein-protein interaction | Leucine-rich repeat protein                     | NA        | CPN2          | Lrrc15        | CG16974              | CYR1    |
| F38H4.3        |                     | RNA processing              | Nucleolar phosphoprotein                        | ++        | NOLC1         |               |                      | SRP40   |
| F52B5.5        | <i>cep-1</i>        | Transcription factor        | p53-like protein                                | +         |               |               |                      |         |
| F52C6.4        |                     | Protein turnover            | Ubiquitin-like protein                          | +         | UBA52         |               | Ubi-p5E              | UBI4    |
| F54D1.5        | <i>gtl-2</i>        | Signal transduction         | TRP calcium channel                             | ++        | TRPM3         | Trpm3         | CG34123              |         |
| F54F11.3       | <i>sre-45</i>       | Signal transduction         | G protein-coupled 7-transmembrane receptor      | NA        |               |               |                      |         |
| F54G8.3        | <i>ina-1</i>        | Signal transduction         | Alpha integrin subunit                          | +         | ITGA6         | Itga6         | mew                  |         |
| H21P03.3       | <i>sms-1</i>        | Metabolism                  | Sphingomyelin synthase                          | +++       | SGMS2         | Sgms2         | SMSr                 |         |
| K01A6.2        | <i>magi-1</i>       | Signal transduction         | MAGI/S-SCAM family protein                      | ++        | MAGI3         | Magi1         | Magi                 | MAGI    |
| K07C6.6        | <i>srx-63</i>       | Signal transduction         | G protein-coupled 7-transmembrane receptor      | +         |               |               |                      |         |
| K10B2.5        | <i>ani-2</i>        | Cell structure              | Actin-binding protein Anillin                   | +         | ANLN          | Anln          | scra                 |         |
| M04D8.2        | <i>ins-22</i>       | Signal transduction         | Type-alpha insulin-like peptide                 | +         |               |               |                      |         |
| R09H10.2       |                     | Metabolism                  | Small molecule methylase                        | +         |               |               |                      |         |
| R107.8         | <i>lin-12</i>       | Signal transduction         | Notch receptor                                  | NA        | NOTCH3        | Notch3        | N                    | AKR1    |
| T02E1.6        |                     | Unknown                     | Novel protein                                   | ++        |               |               |                      |         |
| T05F1.2        |                     | Unknown                     | Novel protein                                   | ++        |               |               |                      |         |
| <b>T09A5.3</b> | <b><i>acr-7</i></b> | <b>Signal transduction</b>  | <b>Alpha-7 nicotinic acetylcholine receptor</b> | <b>++</b> | <b>CHRNA7</b> | <b>Chrna7</b> | <b>nAcRalpha-34E</b> |         |
| T09E11.5       | <i>oac-44</i>       | Metabolism                  | Acyltransferase                                 | +++       |               |               |                      |         |
| T21B4.7        | <i>srh-69</i>       | Signal transduction         | G protein-coupled 7-transmembrane receptor      | NA        |               |               |                      |         |
| T22C8.3        |                     | Transcription factor        | C2H2-type zinc-finger protein                   | NA        |               |               |                      |         |
| T26E3.5        |                     | Protein-protein interaction | F-box protein                                   | NA        |               |               |                      |         |
| W03F8.2        |                     | Signal transduction         | Tyrosine kinase FER                             | NA        | FER           | Fer           | CG8874               | MKK2    |
| W09G10.5       | <i>clec-126</i>     | Cell surface                | C-type lectin                                   | +         | CLEC4M        | Clec4g        |                      |         |
| Y48A6B.5       | <i>exos-1</i>       | RNA processing              | Exosomal subunit                                | NA        | EXOSC1        | Exosc1        | Csl4                 | CSL4    |
| Y106G6H.7      | <i>sec-8</i>        | Signal transduction         | Exocyst complex subunit                         | +         | EXOC4         | Exoc4         | sec8                 | SEC8    |
| ZC168.6        | <i>ssp-34</i>       | Unknown                     | MSP domain-containing protein                   | ++        |               |               |                      |         |
| ZK546.2        |                     | Protein-protein interaction | Leucine-rich repeat protein                     | ++        | LRRCS7        | Lrrc57        | CG3040               | CYR1    |
| ZK593.6        | <i>lgg-2</i>        | Cell structure              | Microtubule-associated protein                  | ++        | MAP1LC3A      | Map1lc3a      |                      | ATG8    |
| ZK896.6        | <i>clec-187</i>     | Cell surface                | C-type lectin                                   | +++       | MRC2          | Mrc2          |                      |         |

Genes were listed alphabetically by sequence name, followed by their locus, functional group, brief description, and suppression score. *Hs*, *Mm*, *Dm*, and *Sc* refer to human, mouse, fly, and yeast, respectively. Homologs were found by searching the Wormbase and NCBI databases. In some cases, sequences were aligned with ClustalW to confirm assignments. The suppressor *acr-7* (in bold) is homologous to a number of human  $\alpha$ -like nAChRs.  
doi:10.1371/journal.pgen.1003313.t001



**Figure 2. Functional diversity of *scla* genes.** Genes were classified by biological process based on Gene Ontology terms from Wormbase. The percentages for each functional class of genes required for suppression of clozapine-induced larval arrest are shown. doi:10.1371/journal.pgen.1003313.g002

effects of clozapine and nicotine are the first phenotypes to be identified in *acr-7* mutants [34].

#### Mutations in *cha-1* or *unc-17* failed to suppress clozapine-induced larval arrest

Our results did not exclude the possibility that clozapine might activate ACR-7 by triggering release of acetylcholine (ACh). If clozapine does so, then mutations in genes required for ACh release should have suppressed clozapine-induced developmental delay. We tested two alleles of the choline acetyltransferase gene *cha-1* and two alleles of the synaptic vesicle ACh transporter gene *unc-17* for suppression of clozapine-induced developmental delay [35,36]. Although both genes are required for ACh release, we found that mutations in *cha-1* or *unc-17* were not suppressors, suggesting that clozapine did not cause developmental delay by stimulating ACh release (Figure 6).

#### *acr-7* was expressed in pharyngeal muscle


We generated transgenic lines expressing a *Pacr-7::GFP* transcriptional fusion construct or a *Pacr-7::acr-7::GFP* translational fusion construct. In both cases, GFP was strongly expressed in the pharyngeal muscles of transgenic animals (Figure 7A). Using pharyngeal pumping and fluorescent bead assays, we previously showed that clozapine caused dose-dependent inhibition of pharyngeal pumping [12]. Inhibition of pharyngeal pumping causes larval arrest in *C. elegans* [37]. Thus, clozapine likely delayed development, in part, by inhibiting pharyngeal pumping.

What is the mechanism by which clozapine inhibited pharyngeal pumping? The *C. elegans* pharynx receives cholinergic innervation from three types of pharyngeal motor neurons: M1,

M2, and M5 [38]. Nicotine inhibited pharyngeal pumping by causing tetanic contraction of pharyngeal muscle [37]. Therefore, we hypothesized that clozapine or the biologically active clozapine metabolite *N*-desmethylclozapine [39] activated pharyngeal muscle ACR-7 channels, causing tetanus with consequent larval arrest. We further hypothesized that *acr-7(tm863)* and *acr-7(RNAi)* loss-of-function mutations blocked activation by clozapine and thereby suppressed pharyngeal paralysis and larval arrest.

#### Knockout of *acr-7* suppressed clozapine-induced inhibition of pharyngeal pumping

Clozapine inhibited pharyngeal pumping of wild-type animals in a concentration-dependent manner. On average the pumping rate in the absence of clozapine was  $112.7 \pm 1.4$  pumps/20 sec, whereas the pumping rate in the presence of clozapine was  $59.0 \pm 4.0$  pumps/20 sec (160  $\mu$ M),  $34.4 \pm 3.7$  pumps/20 sec (320  $\mu$ M), and  $16.8 \pm 2.5$  pumps/20 sec (500  $\mu$ M) (Figure 7B,  $P < 0.0001$ , unpaired *t*-test). The pharyngeal pumping rate of *acr-7(tm863)* mutants was slightly decreased compared to wild type. The mean pumping rate of *acr-7(tm863)* mutants in the absence of drug was  $103.1 \pm 1.2$  pumps/20 sec (Figure 7B,  $P < 0.05$ , unpaired *t*-test). That the *acr-7(tm863)* mutant displays a relatively normal pumping rate argues against a model in which *acr-7* is required for pumping and clozapine inhibits this function. However, the *acr-7(tm863)* deletion suppressed clozapine-induced inhibition of pharyngeal pumping. While the mean pumping rate at 500  $\mu$ M clozapine was  $16.8 \pm 2.5$  pumps/20 sec for N2 animals, the rate for *acr-7(tm863)* mutants was  $40.9 \pm 2.9$  pumps/20 sec (Figure 7B,  $P < 0.0001$ , unpaired *t*-test). Compared to *acr-7(tm863)* mutants, *acr-7(tm863) mchEx40* animals were partially rescued for this




**Figure 3. ACR-7 protein sequence alignment and *acr-7* gene structure.** (A) The *C. elegans* ACR-7 protein and human  $\alpha 7$ -nAChR subunit CHRNA7 were aligned using ClustalW. The four putative transmembrane domains, as predicted for the human CHRNA7 protein, were boxed. nAChRs are members of the *cys*-loop family of ionotropic neurotransmitter receptors, and this conserved di-cysteine loop is dotted line-boxed.  $\alpha$ -nAChR subunits contain a pair of vicinal cysteines within the Ach binding site, and these residues are marked with asterisks. The *C. elegans* and human proteins share 36% identity overall and 41% identity within the pore-lining transmembrane domain II (M2). (B) The *acr-7* gene contains 13 exons, and the region deleted in the *tm863* allele is marked with a line. *tm863* is an out-of-frame deletion which removes exons 6–7 and most of exons 5 and 8. (C) The *tm863* knockout is predicted to lack all four transmembrane domains and to be a null allele.  
doi:10.1371/journal.pgen.1003313.g003

suppression with a mean pumping rate of  $29.3 \pm 2.9$  pumps/20 sec at 500  $\mu$ M clozapine (Figure 7B,  $P < 0.01$ , unpaired *t*-test).

In order to test whether ACR-7 acts specifically in pharyngeal muscle to affect pumping, we generated transgenic lines expressing *Pmyo-2::acr-7* or *Pmyo-2::acr-7::GFP* translational fusion constructs. *myo-2* encodes a myosin heavy chain gene expressed exclusively in pharyngeal muscle. *acr-7(tm863) mchEx207* animals, expressing the *Pmyo-2::acr-7* transgene, were rescued for suppression of clozapine-induced inhibition of pharyngeal pumping with a mean pumping rate of  $17.3 \pm 1.4$  pumps/20 sec at 500  $\mu$ M clozapine (Figure 7B,  $P < 0.001$ , unpaired *t*-test). *acr-7(tm863) mchEx207* animals were

also rescued for suppression of clozapine-induced developmental delay (Figure 4A). *acr-7(tm863) mchEx211* animals, expressing the *Pmyo-2::acr-7::GFP* transgene, displayed strong fluorescence in the pharyngeal muscles and were rescued for both the pharyngeal pumping and developmental phenotypes. Thus, *acr-7* was required in pharyngeal muscle for clozapine-induced inhibition of pharyngeal pumping and for clozapine-induced developmental delay.

Nicotine and levamisole phenocopied clozapine's inhibition of pharyngeal pumping. The mean pumping rate of N2 animals was  $58.1 \pm 2.9$  pumps/20 sec in 2 mM nicotine (Figure 7C,  $P < 0.0001$ , unpaired *t*-test) and 0.0 pumps/20 sec in 300  $\mu$ M levamisole (data



**Figure 4. Genetic and pharmacological characterization of clozapine-induced larval arrest.** (A) Clozapine induced developmental delay in wild-type *C. elegans* in a concentration-dependent manner. *acr-7(tm863)* partially suppressed this developmental delay, and the suppression was rescued by expression of ACR-7 in the mutant background. Expression was driven by a putative *acr-7* promoter in the case of *acr-7(tm863) mchEx40* or by the pharyngeal muscle-specific *myo-2* promoter in the case of *acr-7(tm863) mchEx207*. Growth was measured as the percentage of different development stages 72 hours after loading synchronized L1 animals into the drug plates. Different concentrations (80, 160, 320  $\mu$ M) of clozapine were dissolved in DMSO with the maximum concentration of DMSO being 0.1%. 0.1% DMSO alone was used for control wells. (B) nAChR agonists nicotine (Nico) and levamisole (Leva) induced developmental delay in a concentration-dependent manner, mimicking the effect of clozapine. (C) Nicotine-induced developmental delay is suppressed by *acr-7(tm863)*, and suppression was partially rescued by expression of full-length ACR-7 in the mutant background. (D) Nicotine receptor antagonists d-TC (100 and 500  $\mu$ M) and DH $\beta$ E (100 and 500  $\mu$ M) suppressed clozapine (Cloz)-induced developmental delay. d-TC or DH $\beta$ E alone did not affect the growth of the animals at 100 and 500  $\mu$ M. doi:10.1371/journal.pgen.1003313.g004


not shown). d-TC alone did not change the pumping rate in wild-type animals, similar to the relatively normal pharyngeal pumping rate seen with *acr-7* knockout. However, d-TC did block inhibition of pharyngeal pumping by either clozapine or nicotine. The mean pumping rate of wild-type animals in 500  $\mu$ M clozapine was  $25.3 \pm 3.1$  pumps/20 sec (Figure 7C,  $P < 0.0001$ , unpaired *t*-test), compared to  $69.5 \pm 4.9$  pumps/20 sec with co-application of 500  $\mu$ M d-TC (Figure 7C,  $P < 0.0001$ , unpaired *t*-test). The mean pumping rate of wild-type animals in 2 mM nicotine was significantly increased to  $68.5 \pm 3.7$  pumps/20 sec with co-application of 500  $\mu$ M d-TC, compared to wild-type animals in 2 mM nicotine alone (Figure 7C,  $P < 0.05$ , unpaired *t*-test). However, d-TC failed to block the residual inhibition of pharyngeal pumping produced by either clozapine or nicotine in

*acr-7(tm863)* mutants, indicating that *acr-7* knockout occludes the effect of d-TC (Figure 7D). These results suggested that clozapine and nicotine inhibit pharyngeal pumping, in part, by activating ACR-7 receptors in the pharynx.

## Discussion

Clozapine exposure during adulthood modulates several *C. elegans* behaviors, such as enhancement of egg-laying [11] and inhibition of pharyngeal pumping [12,19] and locomotion. In addition, clozapine exposure during early development produces larval arrest in *C. elegans* [12,20], an effect that may relate to human developmental abnormalities associated with clozapine treatment during pregnancy [20,40]. High drug concentrations







**Figure 5. Suppression by *acr-7(lf)* is specific.** A series of 22 nAChR mutants were tested for suppression of clozapine-induced larval arrest, and only *acr-7(lf)* produced robust suppression. doi:10.1371/journal.pgen.1003313.g005

are required for penetration of the *C. elegans* cuticle [41], but we used HPLC to show that clozapine levels required to produce larval arrest in *C. elegans* (~18 µg/ml) [12] are close to those expected in brains of human patients treated with clozapine

(~11 µg/ml) [42,43]. We employed clozapine-induced developmental delay to perform a genome-wide RNAi screen in *C. elegans* for *scla* genes and identified 40 candidate suppressors of clozapine-induced larval arrest. Several suppressors, such as *magi-1*, *lin-12*,



**Figure 6. Ach release was not the mechanism of clozapine-induced larval arrest.** Mutations in genes required for Ach release failed to suppress clozapine-induced developmental delay. Strong loss-of-function of the choline acetyltransferase gene *cha-1* or the synaptic vesicle Ach transporter gene *unc-17* alone produced developmental delay. Therefore, both weak (*n2411* or *e113*) and strong (*p1152* or *e245*) loss-of-function alleles were tested. doi:10.1371/journal.pgen.1003313.g006



**Figure 7. ACR-7 acted in the pharyngeal muscle.** (A) ACR-7 was highly expressed in the pharynx as indicated by the arrows. A, anterior; P, posterior; D, dorsal; V, ventral. Scattered expression was also observed in the tail and vulval regions. (B) Clozapine inhibited pharyngeal pumping in wild-type animals in a concentration-dependent manner. Suppression of clozapine-induced inhibition of pharyngeal pumping was seen in *acr-7(tm863)* animals, and rescue was observed with expression of ACR-7 in the mutant background. A putative *acr-7* promoter was utilized to drive expression for the *acr-7(tm863) mchEx40* strain, whereas the pharyngeal muscle-specific *myo-2* promoter was utilized for the *acr-7(tm863) mchEx207* strain. (C) Both nicotine and clozapine inhibited the pumping rate in N2 animals. d-TC partially blocked these effects. Importantly, d-TC alone had no effect on pumping. (D) d-TC failed to block clozapine- or nicotine-induced inhibition of pumping in *acr-7(lf)* animals. \*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.0001$ .

doi:10.1371/journal.pgen.1003313.g007

and *ina-1*, have human orthologs implicated in the pathogenesis of schizophrenia but have not been previously shown to mediate the biological effects of an APD [44–46].

The molecular mechanisms of action of human disease genes underlying psychotic disorders are largely unclear. The identification of candidate APD targets in a genetic model organism with a nervous system afforded us the opportunity to analyze the mechanism of action of one such target in detail. However, elucidating the mechanisms underlying APD modulation of ACR-7 cannot fully explain the effects of APDs on *C. elegans*. Several lines of evidence indicate that clozapine-induced larval arrest involves multiple genetic pathways. First, the number and diversity

of suppressors to emerge from our screen suggest that they may not constitute a single pathway. Second, clozapine’s developmental and behavioral effects in *C. elegans* are partially, not fully, suppressed by *acr-7(lf)* (Figure 4A and Figure 7B). Third, other pathways, such as the insulin signaling pathway, are known to be involved [11,12,14]. Previously, we used a candidate gene approach to show that mutations in the *C. elegans* insulin/IGF receptor ortholog *daf-2* and in its downstream effector the phosphatidylinositol 3-kinase (PI3K) *age-1* suppressed clozapine-induced larval arrest. Subsequent work confirmed the discovery that clozapine activates insulin signaling in *C. elegans* and showed that other APDs do so as well [13,14]. Of note, *acr-7* and *age-1* may

act in concert to mediate APD effects in *C. elegans*, since the  $\alpha 7$ -nAChR has been shown to transduce signals to PI3K via direct physical association in rat cortical cultures [47]. Fourth, clozapine has moderate-to-high affinity for many neurotransmitter receptors, and its complex pharmacology may well underlie its clinical superiority. Indeed, 'selectively non-selective' drugs or 'magic shotguns' with affinity for multiple specific targets with synergistic effects may prove to be more effective medications for the treatment of schizophrenia than selective drugs ('magic bullets') that hit one target [5]. Therefore, it will be important to understand not only how nAChR homologs might mediate therapeutic or toxic effects of clozapine, but also how other suppressors might do so. With this end in mind, detailed characterization of several other suppressors is now underway in our laboratory. These studies might provide evidence on how different actions of clozapine interact.

We would also like to know whether particular suppressors mediate clozapine-specific effects or mediate APD effects more generally. To address the question of specificity will require identifying the cellular and molecular mechanisms of suppression for particular mutants and then testing the relevance of those mechanisms for APDs other than clozapine. If the role of a suppressor is clozapine-specific, that target may help explain clozapine's unique therapeutic or toxic effects. If the role is not clozapine-specific, that target may help identify novel mechanisms of action of APDs in general. Importantly then, further characterization of suppressors from our screen may advance the field whether suppression is a clozapine-specific effect or is a characteristic of APDs in general.

Although some RNAi suppressors may act indirectly, some may have human homologs that directly mediate either therapeutic or toxic effects of clozapine. Based on the fact that *cha-1(lf)* and *unc-17(lf)* alleles failed to suppress clozapine-induced larval arrest, we hypothesized that clozapine does not stimulate Ach release, but rather that clozapine modulates ACR-7 directly. Particularly in whole-organism studies, direct effects can be pharmacologically complex, involving activation, inhibition, or a combination of the two. For instance, clozapine acts as an agonist at the human muscarinic M1 receptor, while its biologically active metabolite, *N*-desmethylclozapine, acts as an antagonist [39,48]. Such pharmacological complexity is relevant in the case of nAChRs specifically, where, for example, addition of a methyl group at the amine moiety of cocaine changes that drug's profile from noncompetitive antagonist to agonist [49]. To clarify the mechanism whereby clozapine modulates ACR-7, we undertook a series of genetic, pharmacological, developmental, and behavioral studies in *C. elegans*.

We showed that that *acr-7* mutants suppressed clozapine-induced developmental delay and that a full-length translational *Pacr-7::acr-7::GFP* fusion construct rescued this effect. *acr-7* was strongly expressed in the *C. elegans* pharynx, and *acr-7* knockout suppressed clozapine-induced inhibition of pharyngeal pumping. Furthermore, a translational *Pmyo-2::acr-7* fusion construct rescued suppression of the developmental delay and pharyngeal pumping phenotypes, indicating that ACR-7 acts specifically in pharyngeal muscle cells to mediate these phenotypes. These results suggested that clozapine activates ACR-7 to inhibit pharyngeal pumping and, thereby, produce larval arrest. Consistent with this model, nAChR agonists phenocopied both the developmental and behavioral effects of clozapine. Similarly, nicotine-induced developmental delay required *acr-7*. However, *acr-7(tm863)* did not block nicotine-induced inhibition of pharyngeal pumping, suggesting that nicotine may act through multiple nAChRs to inhibit pharyngeal pumping (Figure 7C and 7D).

Also consistent with our model, nAChR antagonists suppressed clozapine-induced developmental delay and clozapine-induced inhibition of pharyngeal pumping. The results indicated that, as predicted on the basis of sequence information, *acr-7* encodes a nAChR. Suppression of the effects of nicotine and clozapine on pharyngeal pumping and development are the first phenotypes to be identified in *acr-7* mutants [34]. As noted above, clozapine's effects at the whole-organism level may be pharmacologically complex, involving activation, inhibition, or both, but the simplest model to explain our results is that clozapine activates ACR-7. Thus, our data pointed to a novel finding - the existence of nAChRs that are activated by clozapine and/or the biologically active clozapine metabolite *N*-desmethylclozapine [39].

A wealth of evidence has implicated nAChR expression and function in general, and the  $\alpha 7$ -nAChR in particular, in the pathogenesis of schizophrenia [15–17,50], a psychotic disorder for which clozapine appears to be the most effective medication [2–4]. First, decreased nAChR expression has been reported in a number of brain regions of schizophrenics [51–54]. Second, schizophrenics smoke more frequently than the general population, and nicotine exposure has been shown to improve cognition in animals and humans. Therefore, increased smoking in schizophrenics may represent an attempt to self-medicate for cognitive deficits associated with the disease [50]. Third, genetic studies have linked the human  $\alpha 7$ -nAChR gene (CHRNA7) to defective gating of the P50 auditory evoked response, which is related to attentional abnormalities in schizophrenia [17]. Finally,  $\alpha 7$ -nAChR agonists are currently in development for the treatment of psychosis, although no known APDs have been demonstrated to act by this mechanism [16].

Previous reports have suggested that clozapine inhibits the function of  $\alpha 7$ -nAChRs [55,56]. However, inhibition may be specific to the background of the receptor or to species-specific sequence differences [29,57,58]. Moreover, our RNAi screen was designed to identify targets activated by clozapine, since we screened for suppression of the drug's effects by gene knockdown. Interestingly, clozapine improved a schizophrenia-like endophenotype in mice via stimulation of  $\alpha 7$ -nAChRs, although this effect was hypothesized to be indirect [59].

*C. elegans* has at least 29 different nAChR subunits grouped into five subfamilies based on homology: DEG-3-like, UNC-38-like, ACR-8-like, UNC-29-like, and ACR-16-like nAChRs [28,29]. ACR-7 is a member of the ACR-16-like group of nAChR subunits, a group that shows homology to the vertebrate  $\alpha 7$ -10 nAChRs [28,29]. Importantly, we do not know which human  $\alpha$ -like subunit is the ACR-7 ortholog. For example, although *acr-16* showed homology to the vertebrate  $\alpha 7$ -10 nAChRs, a mouse  $\alpha 4\beta 2$  nAChR transgene driven by the *acr-16* promoter rescued nicotine-dependent behaviors in the *acr-16* mutant background, while a mouse  $\alpha 7$  nAChR transgene did not [60].

Mammals have at least 17 different nAChR subunits [28,30], and these nAChRs may assemble in a wide variety of functional combinations [31,61]. Of these, nine different  $\alpha$ -nAChR subunits have been cloned from mammalian tissues to date and have been shown to form homopentamers or heteropentamers [30,61]. Effects of APDs on the spectrum of nAChR subunit combinations have not been tested [62–65]. Therefore, whether APDs can activate one or more of these receptors is an important question, and finding such an interaction would constitute an important breakthrough in APD drug development.

In summary, we conducted the first genetic suppressor screen for APD targets in an animal. We then used the experimental advantages of *C. elegans* neurobiology and neurogenetics to delineate the novel molecular mechanism of action of a specific

APD target.  $\alpha$ -like nAChR signaling is a mechanism through which clozapine may produce its therapeutic and/or toxic effects in humans. This project was designed to translate basic findings in *C. elegans* into clinical applications. Identification of new mechanisms underlying the actions of APDs may lead to changes in both concepts and better-targeted treatments in psychiatric neurobiology.

## Materials and Methods

### Strains

We used the *C. elegans* Bristol strain N2 as the wild-type parent of our mutant strains and grew nematodes under standard culture conditions. Strains were maintained at 20°C. The mutant strains used in our experiments are provided in Table S1. The *age-1(hx546) II* mutation in strain TJ1052 had been backcrossed to the N2 strain three times, and we performed another three backcrosses to generate strain EAB100. The presence of the mutation was followed by restriction digest and confirmed by DNA sequencing. We backcrossed the following mutations to the N2 strain six times to generate strains: EAB1 *sms-1(ok2399) IV*, EAB101 *scla-1(tm4806) IV*, EAB102 *scla-1(tm4534) IV*, EAB103 *ins-22(ok3616) III*, EAB200 *acr-7(tm863) II*, and EAB201 *acr-16(ok789) V* from strains RB1854, *F22B3.8(tm4806)*, *F22B3.8(tm4534)*, RB2594, FX863, and RB918, respectively. The presence of the deletions was followed by PCR.

### RNAi screen

We employed an RNAi feeding library (Geneservice Ltd), constructed by J. Ahringer's laboratory at the The Wellcome CRC Institute, University of Cambridge, Cambridge, England, to carry out a genome-wide screen in liquid culture for suppressors of clozapine-induced larval arrest [21]. Our protocol for feeding RNAi bacteria to animals in liquid culture was adapted from Nollen et al. (2004) [66]. Each RNAi culture was grown overnight at 37°C in 500  $\mu$ l of LB with 100  $\mu$ g/ml of ampicillin. The cultures were induced for four hours the following day by adding 1 ml of LB containing 100  $\mu$ g/ml ampicillin and 1 mM isopropylthiogalactoside (IPTG) in a 37°C incubator. We transferred 200  $\mu$ l of the induced cultures to 96-well plates and centrifuged them at 3000 rpm for 2 minutes. The supernatant was removed, and the induced bacterial pellet was resuspended in 100  $\mu$ l of S-Basal. We then added 50  $\mu$ l of solution containing S-Basal, 50  $\mu$ g/ml ampicillin, 1 mM IPTG, and ~3–5 synchronized L1 *rif-3* animals. These animals were maintained in liquid culture at 20°C on a rotating platform for three days until they reached young adulthood. We then added 1.5  $\mu$ l of clozapine stock solution (20 mg/ml clozapine powder from Sigma-Aldrich #C6305 in 100% ethanol) to each well for a final concentration of 200  $\mu$ g/ml (~600  $\mu$ M) clozapine. Progeny were scored for suppression of clozapine-induced larval arrest on day 8 (Figure 1A). Wells containing progeny that had developed to the L4 stage or beyond were scored as positives (Figure 1B). Those wells lacking progeny or containing contamination were retested. Each set included wells with *dpy-6* RNAi in the absence of clozapine and blank wells in the presence of clozapine as controls.

Positive wells from the genome-wide RNAi screen in liquid culture were tested in triplicate using feeding RNAi on plates containing Nematode Growth Medium (NGM). Each set included triplicate wells of *dpy-6* RNAi and *unc-44* RNAi with and without clozapine as controls. Those wells lacking progeny, lacking a lawn, or containing contamination were retested. Mutants that produced suppression in at least 2/3 wells were taken to be positives, and the strength of suppression was scored: weak (+) - few progeny escaped

larval arrest, medium (++) - ~25% of progeny escaped larval arrest, robust (+++) - most progeny escaped larval arrest, NA - not scored (Table 1). The identity of triplicate positives was verified by sequencing plasmid DNA (MGH DNA Sequencing Core) using primer M13 (Integrated DNA Technologies, Inc.) and then blasting those sequences against the *C. elegans* genome using Wormbase BLAT. Triplicate positives without preexisting gene names and validated by knockout testing were assigned to the new gene name class *scla* for Suppressor of Clozapine-induced Larval Arrest.

### Plasmid constructions

To generate a *Pacr-7::GFP* transcriptional fusion construct, we PCR-amplified the putative promoter region, including 1.3-kb upstream of the *acr-7* gene, using DNA prepared from adult animals and using primers listed in Table S2. This clone was digested with PstI and XmaI restriction enzymes and ligated into the GFP vector pPD95.75. To generate a *Pacr-7::acr-7::GFP* translational fusion construct, we PCR-amplified the same *acr-7* promoter sequence along with 4.3-kb of *acr-7* genomic sequence, omitting the native stop codon, using DNA prepared from adult animals and using primers listed in Table S2. This clone was digested with PstI and KpnI restriction enzymes, sub-electroporated into pCR-XL-TOPO (Invitrogen, Cat: K4700-10), and then subcloned into pPD95.75. PCR was performed using PrimeSTAR HS DNA Polymerase (Takara Bio Inc.). GFP vector pPD95.75 was obtained from the Fire Lab *C. elegans* Vector Kit (Addgene).

To generate the *Pmyo-2::acr-7* and *Pmyo-2::acr-7::GFP* translational fusion constructs, RNA was isolated from mixed-stage worms, and *acr-7* cDNA was obtained using SuperScript III First-Strand Synthesis System (Invitrogen) with primers listed in Table S2. We then cloned the cDNA into Fire Lab vectors L2531 or L3790 (Addgene) using NheI and KpnI restriction enzymes or SalI and EagI restriction enzymes respectively. These *Pmyo-2* constructs were injected into EAB200 animals using the same protocol described below for injection of the *Pacr-7::acr-7::GFP* construct.

All plasmid constructions were confirmed by sequencing (MGH DNA Sequencing Core).

### Expression analysis

We generated extrachromosomal transgenic strains by microinjecting DNA into the gonads of young adult animals as described [67]. The *Pacr-7::GFP* construct was injected at 25 ng/ $\mu$ l along with the *rol-6(su1006)* marker (pRF4) at 50 ng/ $\mu$ l into N2 animals. The *Pacr-7::acr-7::GFP* construct was injected at 25 ng/ $\mu$ l along with the *Pmyo-3::DsRed2* marker (pHC183; a gift from Antony Jose of the Hunter laboratory) at 40 ng/ $\mu$ l into EAB200 animals. Three to four independent extrachromosomal lines were generated for both the *Pacr-7::GFP* and *Pacr-7::acr-7::GFP* constructs. ACR-7::GFP expression shown here was studied in the EAB40 strain, but similar results were obtained in studies of the EAB20 - 24, EAB39, and EAB41 strains. Animals were placed on a 2% agarose pad on a slide in M9 with 50 mM sodium azide, then covered with a slip and studied by DIC and fluorescence microscopy using a Zeiss Axio Image A1 microscope. Photographs were taken using a 40 $\times$  objective on a confocal laser microscope (Leica TCS, Germany).

### Developmental assays

Experiments were performed using Falcon 12-well plates (Becton Dickinson) containing OP50 bacteria on NGM. Clozapine, nicotine, levamisole, DH $\beta$ E, and d-TC were purchased from Sigma-Aldrich. Olanzapine was purchased from Waterstone Technology. Stock solutions of each drug were prepared in

DMSO and then diluted 1:1000 in water with acetic acid (1:10,000). These diluted solutions were then pipetted onto the agar surrounding the bacterial lawn for final drug concentrations of 40, 80, 160, or 320  $\mu\text{M}$  (0.1% DMSO), and the plates were left to dry overnight. On the next day,  $\sim 30$  synchronized L1 larvae were loaded into each well. Animals were then scored as L1, L2, L3, L4, young adult, or gravid adult at 24, 48, 72, 96 hours.

For stressor experiments, paraquat dichloride, tunicamycin, and DL-Dithiothreitol (DTT) were purchased from Sigma-Aldrich, and sodium dodecyl sulfate (SDS) was purchased from Fisher Scientific. Stock solutions of 10% SDS, 2 M paraquat, or 0.2 M DTT in water or 2.5 mg/ml tunicamycin in DMSO were diluted in M9 and pipetted onto the agar to achieve a range of drug concentrations. On the next day, 5–10 adult animals were placed in each well of a 12-well plate. Adults were allowed to lay 25–50 eggs and then removed. Plates were scored for developmental delay and lethality each day until the next generation hatched or until all animals died.

### Pharyngeal pumping assays

Drug plates were prepared as described above. Synchronized L1 larvae were grown to the L4 stage and picked 24 hours in advance of the experiments. Five adult animals were transferred into drug wells or control wells (0.1% DMSO alone). Two hours later, the number of pumps during 20 seconds was scored. Only animals on the bacterial lawn were scored.

### Statistical analysis

Data were expressed as means  $\pm$  S.E.M. Statistical comparisons were performed using the unpaired, two-tailed Student's *t*-test and one-way ANOVA test where appropriate.

### Supporting Information

**Figure S1** RNAi screen mutants did not suppress stressor-induced developmental delay. (A) Developmental delay seen with

SDS or paraquat after 24 hours. (B) Developmental delay seen with SDS or paraquat after 48 hours. For control conditions, vehicle alone was applied to the agar. Paraquat at 0.5 mM produced significant lethality at 48 hours (data not shown). (PDF)

**Table S1** List of mutant strains used in these studies. Dr. L. Chen (University of Minnesota, Minneapolis, MN) provided LH202. Dr. C. Hunter (Harvard University, Cambridge, MA) provided NL4256. Dr. Y. Jin (UCSD, La Jolla, CA) provided CZ9957. Dr. S. Mitani (NBP-Japan) provided *F22B3.8(tm4806) IV* and *F22B3.8(tm4534) IV*. All other strains used in this work, except strains EAB1 through EAB211, were provided by the *Caenorhabditis* Genetics Center, which is funded by the NIH National Center for Research Resources (NCRR). NA, not available. (PDF)

**Table S2** List of primers used for plasmid constructions. (PDF)

### Acknowledgments

We thank Buttner lab members for advice and discussions, and Theresa Stiernagle at the *C. elegans* Genetic Center and the National BioResource Project (Tokyo, Japan) for strains used in this work. We thank Drs. Michael M. Francis, Hilary Prescott, and Navonil Banerjee in the Department of Neurobiology at University of Massachusetts Medical School for assistance with two-electrode voltage-clamp recordings of *Xenopus laevis* oocytes and Drs. David Clapham and Longjun Wu in the Department of Neurobiology at Harvard Medical School and the Howard Hughes Medical Institute for assistance with whole-cell voltage-clamp recordings of cultured HEK293T and PC12 cells.

### Author Contributions

Conceived and designed the experiments: TS LH XW BMC EAB. Performed the experiments: TS SED AO GRS LH XW EAB. Analyzed the data: TS SED AO GRS LH XW EAB. Wrote the paper: TS AO LH XW BMC EAB.

### References

- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 353: 1209–1223.
- Agid O, Foussias G, Singh S, Remington G (2010) Where to position clozapine: re examining the evidence. *Can J Psychiatry* 55: 677–684.
- McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *Am J Psychiatry* 163: 600–610.
- Meltzer HY, Alphas L, Green AI, Altamura AC, Anand R, et al. (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry* 60: 82–91.
- Gray JA, Roth BL (2007) The pipeline and future of drug development in schizophrenia. *Mol Psychiatry* 12: 904–922.
- Meltzer HY (2004) What's atypical about atypical antipsychotic drugs? *Curr Opin Pharmacol* 4: 53–57.
- Dranovsky A, Hen R (2006) Hippocampal neurogenesis: regulation by stress and antidepressants. *Biol Psychiatry* 59: 1136–1143.
- Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, et al. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science* 301: 805–809.
- Burne T, Scott E, van Swinderen B, Hilliard M, Reinhard J, et al. (2011) Big ideas for small brains: what can psychiatry learn from worms, flies, bees and fish? *Mol Psychiatry* 16: 7–16.
- Wang X, Sliwoski GR, Buttner EA (2011) The relevance of *Caenorhabditis elegans* genetics for understanding human psychiatric disease. *Harv Rev Psychiatry* 19: 210–218.
- Karmacharya R, Lynn SK, Demarco S, Ortiz A, Wang X, et al. (2011) Behavioral effects of clozapine: involvement of trace amine pathways in *C. elegans* and *M. musculus*. *Brain Res* 1393: 91–99.
- Karmacharya R, Sliwoski GR, Lundy MY, Suckow RF, Cohen BM, et al. (2009) Clozapine interaction with phosphatidylinositol 3-kinase (PI3K)/insulin-signaling pathway in *Caenorhabditis elegans*. *Neuropsychopharmacology* 34: 1968–1978.
- Weeks KR, Dwyer DS, Aamodt EJ (2011) Clozapine and lithium require *Caenorhabditis elegans* beta-arrestin and serum- and glucocorticoid-inducible kinase to affect Daf-16 (FOXO) localization. *J Neurosci Res* 89: 1658–1665.
- Weeks KR, Dwyer DS, Aamodt EJ (2010) Antipsychotic drugs activate the *C. elegans* Akt pathway via the DAF-2 insulin/IGF-1 receptor. *ACS Chem Neurosci* 1: 463–473.
- Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. *Mol Psychiatry* 10: 40–68.
- Jones CK, Byun N, Bubser M (2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. *Neuropsychopharmacology* 37: 16–42.
- Martin LF, Freedman R (2007) Schizophrenia and the alpha7 nicotinic acetylcholine receptor. *Int Rev Neurobiol* 78: 225–246.
- Ericson E, Gebbia M, Heisler LE, Wildenhain J, Tyers M, et al. (2008) Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. *PLoS Genet* 4: e1000151. doi:10.1371/journal.pgen.1000151
- Donohoe DR, Jarvis RA, Weeks K, Aamodt EJ, Dwyer DS (2009) Behavioral adaptation in *C. elegans* produced by antipsychotic drugs requires serotonin and is associated with calcium signaling and calcineurin inhibition. *Neurosci Res* 64: 280–289.
- Donohoe DR, Aamodt EJ, Osborn E, Dwyer DS (2006) Antipsychotic drugs disrupt normal development in *Caenorhabditis elegans* via additional mechanisms besides dopamine and serotonin receptors. *Pharmacol Res* 54: 361–372.
- Kamath RS, Ahringer J (2003) Genome-wide RNAi screening in *Caenorhabditis elegans*. *Methods* 30: 313–321.
- Simmer F, Moorman C, van der Linden AM, Kuijck E, van den Berghe PV, et al. (2003) Genome-wide RNAi of *C. elegans* using the hypersensitive *rif-3* strain reveals novel gene functions. *PLoS Biol* 1: e12. doi:10.1371/journal.pbio.0000012
- Harada H, Kurauchi M, Hayashi R, Eki T (2007) Shortened lifespan of nematode *Caenorhabditis elegans* after prolonged exposure to heavy metals and detergents. *Ecotoxicol Environ Saf* 66: 378–383.
- Kondo M, Yanase S, Ishii T, Hartman PS, Matsumoto K, et al. (2005) The p38 signal transduction pathway participates in the oxidative stress-mediated

- translocation of DAF-16 to *Caenorhabditis elegans* nuclei. *Mech Ageing Dev* 126: 642–647.
25. Lee W, Lee TH, Park BJ, Chang JW, Yu JR, et al. (2005) *Caenorhabditis elegans* calnexin is N-glycosylated and required for stress response. *Biochem Biophys Res Commun* 338: 1018–1030.
  26. Struwe WB, Hughes BL, Osborn DW, Boudreau ED, Shaw KM, et al. (2009) Modeling a congenital disorder of glycosylation type I in *C. elegans*: a genome-wide RNAi screen for N-glycosylation-dependent loci. *Glycobiology* 19: 1554–1562.
  27. Kamath RS, Fraser AG, Dong Y, Poulin G, Durbin R, et al. (2003) Systematic functional analysis of the *Caenorhabditis elegans* genome using RNAi. *Nature* 421: 231–237.
  28. Jones AK, Davis P, Hodgkin J, Sattelle DB (2007) The nicotinic acetylcholine receptor gene family of the nematode *Caenorhabditis elegans*: an update on nomenclature. *Invert Neurosci* 7: 129–131.
  29. Jones AK, Sattelle DB (2004) Functional genomics of the nicotinic acetylcholine receptor gene family of the nematode, *Caenorhabditis elegans*. *Bioessays* 26: 39–49.
  30. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. *Physiol Rev* 89: 73–120.
  31. Fucile S (2004) Ca<sup>2+</sup> permeability of nicotinic acetylcholine receptors. *Cell Calcium* 35: 1–8.
  32. Boulin T, Gielen M, Richmond JE, Williams DC, Paoletti P, et al. (2008) Eight genes are required for functional reconstitution of the *Caenorhabditis elegans* levamisole sensitive acetylcholine receptor. *Proc Natl Acad Sci U S A* 105: 18590–18595.
  33. Jospin M, Qi YB, Stawicki TM, Boulin T, Schuske KR, et al. (2009) A neuronal acetylcholine receptor regulates the balance of muscle excitation and inhibition in *Caenorhabditis elegans*. *PLoS Biol* 7: e1000265. doi:10.1371/journal.pbio.1000265
  34. Community TCeR (2011) Wormbase web site, release WS227.
  35. Alfonso A, Grundahl K, Duerr JS, Han HP, Rand JB (1993) The *Caenorhabditis elegans unc-17* gene: a putative vesicular acetylcholine transporter. *Science* 261: 617–619.
  36. Rand JB, Russell RL (1984) Choline acetyltransferase-deficient mutants of the nematode *Caenorhabditis elegans*. *Genetics* 106: 227–248.
  37. Raizen DM, Lee RY, Avery L (1995) Interacting genes required for pharyngeal excitation by motor neuron MC in *Caenorhabditis elegans*. *Genetics* 141: 1365–1382.
  38. Rand JB (2007) *Wormbook: Acetylcholine*.
  39. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, et al. (2003) N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. *Proc Natl Acad Sci U S A* 100: 13674–13679.
  40. Costa LG, Steardo L, Cuomo V (2004) Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects. *Pharmacol Rev* 56: 103–147.
  41. Page AP, Johnstone IL (2007) *Wormbook: The cuticle*.
  42. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, et al. (1993) Tissue concentrations of clozapine and its metabolites in the rat. *Neuropsychopharmacology* 9: 117–124.
  43. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, et al. (1996) Serum levels of clozapine and nortriptyline in patients treated with selective serotonin reuptake inhibitors. *Am J Psychiatry* 153: 820–822.
  44. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, et al. (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science* 320: 539–543.
  45. Walsh MT, Ryan M, Hillmann A, Condren R, Kenny D, et al. (2002) Elevated expression of integrin alpha(IIb) beta(IIIa) in drug-naive, first-episode schizophrenic patients. *Biol Psychiatry* 52: 874–879.
  46. Wang Z, Wei J, Zhang X, Guo Y, Xu Q, et al. (2006) A review and re-evaluation of an association between the NOTCH4 locus and schizophrenia. *Am J Med Genet B Neuropsychiatr Genet* 141B: 902–906.
  47. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, et al. (2001) alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta amyloid-induced neurotoxicity. *J Biol Chem* 276: 13541–13546.
  48. Thomas DR, Dada A, Jones GA, Deisz RA, Gigout S, et al. (2010) N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor. *Neuropharmacology* 58: 1206–1214.
  49. Francis MM, Cheng EY, Weiland GA, Oswald RE (2001) Specific activation of the alpha 7 nicotinic acetylcholine receptor by a quaternary analog of cocaine. *Mol Pharmacol* 60: 71–79.
  50. Mobascher A, Winterer G (2008) The molecular and cellular neurobiology of nicotine abuse in schizophrenia. *Pharmacopsychiatry* 41 Suppl 1: S51–59.
  51. Freedman R, Adams CE, Leonard S (2000) The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. *J Chem Neuroanat* 20: 299–306.
  52. Freedman R, Hall M, Adler LE, Leonard S (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. *Biol Psychiatry* 38: 22–33.
  53. Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, et al. (2003) Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. *Biol Psychiatry* 54: 1222–1233.
  54. Marute A, Zhang X, Court J, Piggott M, Johnson M, et al. (2001) Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. *J Chem Neuroanat* 22: 115–126.
  55. Grinevich VP, Papke RL, Lippiello PM, Bencherif M (2009) Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. *Neuropharmacology* 57: 183–191.
  56. Singhal SK, Zhang L, Morales M, Oz M (2007) Antipsychotic clozapine inhibits the function of alpha7-nicotinic acetylcholine receptors. *Neuropharmacology* 52: 387–394.
  57. Ballivet M, Alliod C, Bertrand S, Bertrand D (1996) Nicotinic acetylcholine receptors in the nematode *Caenorhabditis elegans*. *J Mol Biol* 258: 261–269.
  58. Raymond V, Mongan NP, Sattelle DB (2000) Anthelmintic actions on homomer forming nicotinic acetylcholine receptor subunits: chicken alpha7 and ACR-16 from the nematode *Caenorhabditis elegans*. *Neuroscience* 101: 785–791.
  59. Simosky JK, Stevens KE, Adler LE, Freedman R (2003) Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. *Psychopharmacology (Berl)* 165: 386–396.
  60. Feng Z, Li W, Ward A, Piggott BJ, Larkspur ER, et al. (2006) A *C. elegans* model of nicotine-dependent behavior: regulation by TRP-family channels. *Cell* 127: 621–633.
  61. Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, et al. (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. *Biochem Pharmacol* 78: 703–711.
  62. Wang N, Orr-Urtreger A, Chapman J, Ergun Y, Rabinowitz R, et al. (2005) Hidden function of neuronal nicotinic acetylcholine receptor beta2 subunits in ganglionic transmission: comparison to alpha5 and beta4 subunits. *J Neurosci* 25: 167–177.
  63. Wang F, Gerzanich V, Wells GB, Anand R, Peng X, et al. (1996) Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits. *J Biol Chem* 271: 17656–17665.
  64. Yu CR, Role LW (1998) Functional contribution of the alpha5 subunit to neuronal nicotinic channels expressed by chick sympathetic ganglion neurones. *J Physiol* 509 (Pt 3): 667–681.
  65. Yu CR, Role LW (1998) Functional contribution of the alpha7 subunit to multiple subtypes of nicotinic receptors in embryonic chick sympathetic neurones. *J Physiol* 509 (Pt 3): 651–665.
  66. Nollen EA, Garcia SM, van Haften G, Kim S, Chavez A, et al. (2004) Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. *Proc Natl Acad Sci U S A* 101: 6403–6408.
  67. Mello CC, Kramer JM, Stinchcomb D, Ambros V (1991) Efficient gene transfer in *C. elegans*: extrachromosomal maintenance and integration of transforming sequences. *EMBO J* 10: 3959–3970.